Mid-March Madness of COVID-19: Q120 OrthoBio Market Recap

Written by Kim French | 7/8/20 1:30 PM

The mid-March madness of COVID-19 results in final missed shots for many companies.

For sports fans, March is about celebrating the best in college basketball. Regrettably, March Madness was swapped with COVID-19 mid-March madness, disrupting lives and companies across the world. Since the COVID-19 outbreak, the first corporate earnings season has concluded and we now have a peek of the negative impacts caused by the pandemic and deferral of elective procedures. As for Q120, US orthobiologics revenue declined -5.5% YoY compared to Q119.

Among the many topics covered in the comprehensive Q120 OrthoBio Market Recap* are:

Complete Q120 Market Highlights
All OrthoBio Company Shares and Revenue
Newer Players that are Driving to the Hoop
Q120 Regulatory Highlights

Smith & Nephew*, with REGENETEN*, and Cerapedics*, with i-Factor*, are scoring points in the US orthobiologics market. After spinning off its Biologics division in 2012, Smith & Nephew is directly getting back in the game. Continuing a “zone offense” strategy, Smith & Nephew recognize the synergy of devices, enabling technologies, surgical procedures and orthobiologics. In 2019, the Company formed a Biologics and Regenerative Medicine R&D team that is dedicated to the development of innovative orthobiologics. In late 2017, the REGENETEN technology was acquired, which SmartTRAK believes ...

Read the entire Q120 OrthoBio Market Recap including news, data, charts, company revenues and analysis*...

*The entire article and the links can only be viewed by SmartTRAK subscribers to this module. For more information on how to receive a demo and subscribe, please click the button below.

Learn More

View full post